The anti-atherogenic effects of consuming soy-isoflavones have been demonstrated in a variety of studies. However, the mechanisms involved remain poorly defined. Adhesion of monocytes to vascular endothelial cells is a key step within the inflammatory cascade that leads to atherogenesis. Many factors including the physical forces associated with blood flow regulate this process. Using an in vitro flow assay, we report that genistein, a principal component of most isoflavone preparations, inhibits monocyte adhesion to cytokine (TNFα) stimulated human vascular endothelial cells at physiologically relevant concentrations (0-1µM). This effect is absolutely dependent on flow, and is not observed under static conditions. Furthermore, this inhibition was dependent on activation of endothelial PPARγ (peroxisomal proliferator activated receptor). No significant role for other reported properties of genistein including antioxidant effects, inhibition of tyrosine kinases, nor activation of estrogen receptors was observed. Furthermore, the antiadhesive effects of genistein did not occur via modulation of the adhesion molecules ESelectin, ICAM-1, VCAM-1 or PECAM-1. These data reveal a novel anti-inflammatory mechanism for isoflavones and identify the physical forces associated with blood flow and a critical mediator of this function.
INTRODUCTION
Vascular inflammation has been identified as an early event in the pathogenesis of atherosclerosis (4, 27, 39) . Specifically, interactions of monocytes with the vascular endothelium are stimulated by pro-inflammatory factors including cytokines (e.g. tumor necrosis factor-α, TNF-α) and oxidized lipids(30). Monocytes thereby accumulate in the vessel wall, and in the environment of a developing lesion mature into cholesterol filled macrophages, also referred to as foam cells(24). Recent insights have highlighted a critical role for the endothelium in controlling inflammation and the disease process. In fact, endothelial dysfunction (characterized by loss of flow-mediated dilation) has been suggested as a clinical risk factor for the development of this disease (8, 14) .
Leukocyte-endothelial cell interactions occur early in the inflammatory cascade and involve multiple temporally distinct events. In order, these are i) rolling along the endothelium, i.e. the slowing down of free flowing leukocytes by the endothelium, ii) leukocyte activation for subsequent adhesion, iii) firm adhesion of the leukocyte to the endothelium, and iv) leukocyte transmigration into the sub-endothelial space. The distinct steps are mediated by adhesion molecules expressed on the different cell types involved.
Importantly, these interactions occur in the presence of blood flow and the physical forces associated with this. Therefore in vivo, leukocytes have to overcome physical shearing forces before firmly adhering. Moreover, shear stress (the frictional force of fluid flow experienced by endothelial cells) is itself a potent stimulus regulating antiinflammatory endothelial signaling pathways (10, 33, 43) .
The role of the environment and specifically the diet in either development or protection against atherosclerosis has been the subject of much interest. In the latter case, the primary concept is based on the ability of so-called antioxidants to prevent oxidative damage to low-density lipoprotein and other molecules that in turn, create proatherogenic stimuli (25, 31) . Dietary consumption of antioxidant compounds therefore has been suggested to exert protection by scavenging or detoxification of oxidants. In this regard, polyphenols have been studied extensively. One such class of polyphenols are the soy-isoflavones (7, 25, 42, 47) , consumption of which is associated with a protection against development of cardiovascular disease (37, 41). Furthermore, dietary administration of isoflavones in experimental models of atherosclerosis protect against disease development (28, 49) . The mechanisms through which isoflavones modulate the atherogenic process, however, are not clear and in the circulation must occur at low (<1µM) concentrations of isoflavones found in vivo. At these concentrations, isoflavones are relatively poor antioxidants and we and others have suggested that in vivo, antioxidant effects of isoflavones are likely to be mediated by metabolites and/or interactions with other co-antioxidants (e.g. ascorbate) (5, 17, 32) . Additional insights suggest antiinflammatory effects, anti-thrombotic effects and modulation of endothelial function (15, 38, 44, 45) . However, detailed molecular mechanisms remain unclear.
More recent studies have highlighted the role of modulating specific cellsignaling pathways as mechanisms through which isoflavone consumption modulates inflammatory disease. At low concentrations (nM-µM), the isoflavone genistein (a primary constituent of most isoflavone containing foods), has been shown to bind the β-isoform of the estrogen receptor and activate the peroxisomal proliferator activated receptor-γ (PPARγ) (3, 9, 23) . PPARγ is a nuclear receptor/transcription factor that mediates a variety of anti-inflammatory pathways including down-regulation of leukocyte-endothelial cell interactions (18, 46). Consistent with a regulatory effect on cell signaling, recent studies have demonstrated a critical role for PPARγ in the antiatherosclerotic effects of genistein (28) . However, functional consequences and mechanisms involved in this activity remain unclear.
Given the importance of monocyte-endothelial cell interactions in the early stages of atherogenesis, we hypothesized that a central mechanism for the anti-inflammatory effects of isoflavones would be the inhibition of monocyte adhesion to the vascular endothelium. Using an in vitro approach to assess monocyte adhesion to endothelial cells, our data revealed a novel mechanism of action for isoflavones involving a PPAR-γ dependent inhibition of monocyte-endothelial cell interactions during flow, but not under static conditions. These results reveal a critical role for blood flow and associated physical forces, in modulating the anti-inflammatory effects of isoflavones. All other chemicals used were of analytical grade.
MATERIALS AND METHODS

Materials
Cell culture and viability: Endothelial cells were maintained by splitting (1:4) onto gelatin/fibronectin coated tissue culture flasks, used between passages 3-7 and grown in Endothelial Growth Medium containing 2% FBS, 1 mg/ml penicillin-streptomycin, 1 µg/ ml hydrocortisone, 10 U/ml heparin, 50 µg/ml endothelial mitogen (BioMed. Tech. Inc).
All experiments were within 1 day of cells reaching confluency. THP-1 and HL-60 cells were maintained in RPMI 1640 containing 10%FBS, 1 mg/ml penicillin-streptomycin at 1.5x10 6 cells/ml to maintain them in the log cell growth phase. replicate experiments are shown in corresponding figure legends. The critical velocity of monocytes i.e. the maximum velocity at which a rolling monocyte can travel was calculated using the relation Vcrit = γrβ, where Vcrit is the critical velocity, γ is the shear rate, r is the radius of the rolling monocytes and β is the dimensionless drag coefficient derived from the theoretical analysis of a sphere flowing close to the vessel wall and depends upon the distance between the flowing monocytes and the closest endothelial cell (in this case it is calculated to be 0.5). Only those monocytes that had a velocity less than the critical velocity and for a straight-line distance of more than one THP-1 cell radius were considered for rolling velocity measurements. Calculated critical rolling velocities were 1305 µm/sec for 1.5 dyn/cm 2 ; 665 µm/sec for 0.75 dyn/cm 2 and 435 µm/sec for 0.5 dyn/cm 2 .
Adhesion molecule expression. Expression of the adhesion molecules E-selectin and
PECAM-1 were determined using an ELISA protocol. Briefly. HUVEC (grown in 96-well culture plates) were treated with genistein (1 µM) for 16 hr, followed by TNFα for 4
hr. Cells were washed 3-times with ice-cold PBS, pH 7.4 and then fixed using 1% paraformaldehyde diluted in PBS, for 20 min. Wells were then blocked using 3% BSA in PBS for 1 hr at room temperature. After washing with PBS containing 1% BSA cells were incubated with either anti-E-Selectin, ICAM-1 or PECAM-1 primary antibody for 1 hr at room temperature and followed with the respective peroxidase-labeled secondary antibody for 30 min. Tetramethyl Benzidine (TMB, Sigma Chemical Co.) was used as the soluble substrate and the color was measured at 450 nm using a PerkinElmer Plate reader.
The adhesion molecules VCAM-1 and ICAM-1 were also determined by western blotting. immediately after the addition of oxidants and continued for 30min.
Statistical Evaluation
Experiments were conducted in triplicate and repeated at least three times. For in vitro flow experiments data are plotted as fold changes relative to TNF-α. Significance was assessed using student t-test, taking a value of p<0.05 as significant. Figure 1A shows that treatment of HUVEC with genistein (0-20µM) for 14 hr has no effect on subsequent TNF-α dependent adhesion of THP-1 assessed under static conditions. However, measuring firm-adhesion of THP-1 cells to HUVEC in the presence of flow revealed a significant inhibitory effect of genistein ( Figure 1B ). Importantly, significant inhibition occurred at low biologically relevant concentrations of genistein (between 0-1 µM), and was maximal at 10 µM. In the absence of TNF-α, no adhesion was observed under any treatment condition. Vehicle control (methanol, MeOH) had no effect on TNF-α dependent stimulation of firm-adhesion of THP-1. These data suggest a specific effect of genistein in inhibiting leukocyte adhesion to endothelial cells during flow and inflammation. To ensure that this differential effect of genistein was not due to the different exposure times of THP-1 cells with HUVEC (30mins for static and 1min for flow), the effect of genistein on TNF-α stimulated adhesion under static conditions was determined over a 1minute time period. Figure 1C shows that under this experimental condition, genistein had no effect on TNF-α stimulated adhesion. Figure 2 shows the time-dependent inhibition of THP-1 adhesion to HUVEC treated with genistein at 1µM and 20µM. At a higher (supraphysiological) concentration of genistein, significant inhibition was observed even when the isoflavone was added 2 hr after TNF-α. At the lower (physiological) concentration tested, significant inhibition was only observed when genistein was incubated with HUVEC for 16 hr prior to TNF-α, suggesting that modulation of signaling processes underlie the anti-adhesive effects of this isoflavone. To better assess biologically relevant mechanisms, the remainder of the studies presented utilized genistein concentrations and exposure times of 1 µM and 16 hr, respectively. 
RESULTS
Inhibition of leukocyte-endothelial cell interactions by genistein during flow
Effects of genistein on adhesion molecule expression
Modulating adhesion molecule expression is a common mechanism through which leukocyte-endothelial interactions are controlled (19) . Data shown in Figures 1-4 illustrate a role for genistein in controlling both the rolling and firm adhesion aspects of the inflammatory cascade. To this end we tested the potential for genistein to inhibit TNF-α dependent up-regulation of the adhesion molecules E-selectin, VCAM-1, ICAM-1 and PECAM-1 which are involved in mediating rolling and firm adhesion steps.
Moreover, previous studies show that genistein inhibits VCAM-1 mRNA expression in TNF-α treated endothelial cells (29). Data shown in Table 1 , however, demonstrate that under conditions that inhibit monocyte adhesion during flow, genistein has no effect on TNF-α dependent induction of VCAM-1, nor the other adhesion molecules investigated.
This indicates that TNF-α stimulated inflammatory signaling pathways are intact and functional in genistein treated cells and that anti-adhesive effects of this isoflavone are not mediated via controlling expression of these adhesion molecules. Genistein is a relatively poor antioxidant suggesting at that the low concentrations used in these studies (32) , scavenging of reactive species is an unlikely mechanism. This was further suggested by a lack of any effect of genistein (1µM) in scavenging reactive species in HUVEC generated either by addition of hydrogen peroxide (100-500µM) or addition of the intracellular redox cycling agent, dimethylnapthoquinone (10-50µM) ( Figure 6 ). Finally, genistein is widely used as an experimental tool to inhibit tyrosine kinases, and could therefore underlie the anti-adhesive effects observed. Typically concentrations above 20 µM in endothelial cells are required to inhibit tyrosine kinases, however. Consistent with this thesis, under conditions which resulted in inhibition of adhesion during flow, genistein did not alter changes in tyrosine phosphorylation (as determined by western blotting using an anti-phosphotyrosine antibody) that occurred in response to TNFα (not shown).
Anti-adhesive effects are mediated via PPARγ
To test if the effects of genistein were mediated via activation of PPARγ, the receptor antagonist GW9662 was used. Figure 7A shows that inhibition of PPARγ alone has no effect on TNF-α dependent THP-1 adhesion during flow, but completely abrogates the anti-adhesive effects of genistein. Consistent with a role for PPARγ in inhibiting adhesion during flow, rosiglitazone (a synthetic PPARγ agonist) also attenuated TNFα dependent effects via a mechanism that was sensitive to GW9662 ( Figure 7A ). Similar to genistein, rosiglitazone did not modulate THP-1 adhesion under static conditions ( Figure 7B ). To further illustrate the potential for genistein to activate PPARγ dependent processes, the effect of genistein to stimulate expression of CD36, a molecule widely used as a marker for PPARγ dependent activity was determined in macrophages. Figure 7C shows that genistein significantly (albeit relatively weakly, approximately 1.3-fold) increased CD36 expression which was inhibited by GW9662.
DISCUSSION
Isoflavones have been discussed as potential modulators of a variety of diseases including those of cardiovascular origin, cancer and osteoporosis (2, 12) . In the context of cardiovascular disease, consumption of genistein has been shown to protect against atherogenesis, although detailed molecular mechanisms remain unclear. Most studies have focused on the antioxidant potential of isoflavones, with other effects including modulating lipoprotein metabolism also being reported (6) . In this study we propose a novel mechanism that involves modulation of endothelial responses during inflammation.
Specifically, genistein inhibits an important step of the inflammatory cascade; monocyte adherence to endothelial cells. Given the early and critical requirement for this step in atherogenesis, inhibition by genistein may represent a critical anti-atherosclerotic mechanism for this isoflavone.
The principal finding of this study is that genistein inhibits monoycte adhesion to TNF-α activated endothelial cells in a manner that is absolutely dependent on flow. This is observed through decreases in both the number of rolling and firmly bound monocytes.
Importantly, the inhibitory effects of genistein are observed with primary human monocytes and endothelial cells derived from different vascular beds suggesting a common underlying mechanism that is not specific to the cell types involved. Previous studies investigating the anti-inflammatory properties of isoflavones have shown that genistein inhibits platelet aggregation and release of pro-inflammatory cytokines (15) . In with estrogen receptors was also excluded. Moreover, it is unlikely that genistein is affecting TNF-α signaling since no effect on adhesion molecule expression was observed nor on monocyte adhesion under static conditions. This latter effect does not preclude regulation of adhesion molecules at the post-translation level however nor on regulation of other potential adhesion molecules that may mediate the adhesion process.
PPARγ is recognized as an integral member of pathways that control inflammation (11). In the endothelium, ligands that activate this nuclear receptor result in Interestingly, under our experimental conditions rosiglitazone also did not affect static adhesion, but did inhibit adhesion during flow (Fig 7A-B HUVEC were treated with rosiglitazone (rosi, 2µM, 16hr) in the absence and presence of GW9662 (5µM) followed by TNFα (4hr). Data show mean ± sem (n=4-6) * indicates p <0.01 relative to control. Panel C) Genistein increased CD36 expression in macrophages.
Macrophages were exposed to genistein (1µM, 16hr) in the presence or absence of 
